What does this research mean for the field?

Upadacitinib treatment in biologic-refractory spondyloarthritis patients leads to significant reductions in disease activity and inflammatory markers, while maintaining a stable LDL/HDL ratio despite increases in lipid subfractions. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to assess the short-term metabolic and inflammatory effects of upadacitinib in patients with biologic-refractory spondyloarthritis.

February 25, 2026PharmaceuticsOpen Access

Short-Term Metabolic and Inflammatory Effects of Upadacitinib in Biologic-Refractory Spondyloarthritis: Real-World Evidence on Lipid Paradox and Safety

View Full Paper

Ask AI

Bookmark

This research aims to assess the short-term metabolic and inflammatory effects of upadacitinib in patients with biologic-refractory spondyloarthritis.
Conducted as a retrospective cohort study of 61 patients with spondyloarthritis.
Evaluated UPA treatment effects on disease activity, inflammatory markers, and lipid parameters over three months.
Measured disease activity using BASDAI and inflammatory markers like CRP and ESR at baseline, Month 1, and Month 3.
Significant reductions in BASDAI, CRP, and ESR by Month 3 (p < 0.001 and p < 0.01).
Increased hemoglobin and albumin levels (p < 0.05).
Total cholesterol, LDL-C, and HDL-C also increased significantly (p ≤ 0.003).
No significant changes in triglycerides or LDL/HDL ratio (p > 0.05).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study evaluates short-term impacts of upadacitinib on inflammation and metabolism in spondyloarthritis, suggesting safe cardiovascular reassessment.

Cite This Study

Akar et al. (2026) studied this question.

synapsesocial.com/papers/699e9166f5123be5ed04edba https://doi.org/10.3390/pharmaceutics18020272

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study evaluates short-term impacts of upadacitinib on inflammation and metabolism in spondyloarthritis, suggesting safe cardiovascular reassessment.

Short-Term Metabolic and Inflammatory Effects of Upadacitinib in Biologic-Refractory Spondyloarthritis: Real-World Evidence on Lipid Paradox and Safety

Key Points

Discussion

Implication

Cite This Study

Short-Term Metabolic and Inflammatory Effects of Upadacitinib in Biologic-Refractory Spondyloarthritis: Real-World Evidence on Lipid Paradox and Safety

Key Points

Discussion

Implication

Cite This Study